Prot# CC-11050-CLE-002: A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects with Discoid Lupus Erythematosus and Subacut

Project: Research project

StatusFinished
Effective start/end date12/8/1012/8/13

Funding

  • Celgene Corporation (CC-11050-CLE-002)